Status:

WITHDRAWN

Fluoxetine Essay in Children With Autism

Lead Sponsor:

Assistance Publique - Hôpitaux de Paris

Conditions:

Autism

Eligibility:

All Genders

5-12 years

Phase:

PHASE2

Brief Summary

This study is a comparative, double blind, placebo controlled trial of 6-months duration designed to evaluate 1) the effects of fluoxetine in 5 to 12 years old autistic children, 2) the effects of flu...

Detailed Description

Autism is a severe neurodevelopmental disorder characterized by impaired social interaction and communication, and by a markedly restricted repertoire of activities and interests. The population preva...

Eligibility Criteria

Inclusion

  • Male and female subjects with diagnosis of Pervasive developmental disorder (PDD) meeting all criteria listed bellow will be included in the study:
  • age 5 to 12 years, outpatients.
  • presenting with a primary diagnosis of autism according to DSM- IV-R.
  • Autism will be diagnosed with Autism Diagnostic Interview (ADI)
  • with a score of 30 or above on the Children Autistic Rating Scale (CARS, SCHOPLER et al., 1980).
  • Written informed consent obtained from each patient's parents or legal guardian.

Exclusion

  • Subjects presenting with any of the following will not be included in the study:
  • Participation in any other studies involving investigational or marketed products within 6 months prior to entry in the study.
  • Treatment given for autism within the previous 1 month
  • Organic mental disorder or organic brain syndrome (including epilepsy)
  • Severe mental retardation (IQ \< 45).
  • Specific systemic diseases, including history of significant hematological, endocrine, cardiovascular, renal, gastrointestinal or neurological disease (including more than one episode of childhood febrile convulsion).
  • Medical contra-indication to treatment with any antidepressant and specially sertraline
  • Previous history of intolerance or hypersensitivity to fluoxetine or to drugs with similar chemical structures
  • Currant use of concomitant anticoagulant therapy
  • Previous participation in any other clinical trial with the study drug
  • Require concomitant therapy with any psychotropic drug or with any drug with a psychotropic component

Key Trial Info

Start Date :

September 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2011

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT00873834

Start Date

September 1 2009

End Date

November 1 2011

Last Update

January 10 2012

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.